Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"[⁶⁸Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.","authors":"Stephan Beintner-Skawran, Andrei Gafita, Theo Lorenzini, Robert Tauber, Sebastian Hoberück, Francesco Mattana, Andrea Di Giorgio, Matthias Miederer, Channing J Paller, Loic Djaileb, Lilja B Solnes, Andrea Farolfi, Francesco Ceci, Matthias Eiber, Andrew F Voter","doi":"10.2967/jnumed.125.269584","DOIUrl":"https://doi.org/10.2967/jnumed.125.269584","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) PET has the potential to monitor the response to taxane-based chemotherapy in patients with prostate cancer and shows promise for predicting outcomes and improving response evaluation. This retrospective study aimed to determine the prognostic value of [⁶⁸Ga]Ga-PSMA-11 PET (PSMA PET)-derived quantitative tumor burden parameters for overall survival (OS). <b>Methods:</b> Databases from 6 institutions were screened for patients with prostate cancer who underwent PSMA PET and whose serum prostate-specific antigen (PSA) measurements were recorded at baseline and after completing taxane-based chemotherapy. Tumor segmentation was performed using artificial intelligence-based software, and PSMA PET whole-body quantitative parameters were obtained, including PSMA-positive tumor volume (PSMA-VOL), SUV_max, and SUV_mean Univariate Cox regression analyses were used to evaluate the association of whole-body quantitative PSMA parameters and PSA levels with OS. The Harrell concordance index (C-index) was used to determine prognostic accuracy. Optimal cutoffs were determined by maximizing the log-rank statistic. <b>Results:</b> In total, 128 patients were included in the study; 62 (48%) had hormone-sensitive prostate cancer, and 66 (52%) had castration-resistant prostate cancer. At baseline, PSMA-VOL had the highest prognostic value for OS compared with serum PSA, SUV_max, and SUV_mean (C-index of 0.88, 0.80, 0.69, and 0.29, respectively), whereas the percentage change in PSA levels had the highest prognostic value during treatment compared with percentage change in PSMA-VOL, SUV_max, and SUV_mean (C-index of 0.94, 0.85, 0.90, and 0.85, respectively). <b>Conclusion:</b> Baseline and posttherapeutic PSMA PET quantitative parameters are prognostic for OS after taxane-based chemotherapy in patients with metastatic prostate cancer. Baseline PSMA-VOL had the highest prognostic value for OS, whereas changes in PSA levels outperformed changes in quantitative PSMA PET parameters during treatment.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MIRD Pamphlet No. 33: MIRDpvc-A Software Tool for Recovery Coefficient-Based Partial-Volume Correction.","authors":"Harry Marquis, Johan Gustafsson, C Ross Schmidtlein, Robin de Nijs, Pablo Mínguez Gabiña, Gunjan Kayal, Juan C Ocampo Ramos, Lukas M Carter, Dale L Bailey, Adam L Kesner","doi":"10.2967/jnumed.125.270168","DOIUrl":"https://doi.org/10.2967/jnumed.125.270168","url":null,"abstract":"<p><p>Partial-volume effects (PVEs) arise from the limited spatial resolution of PET and SPECT imaging systems, causing the systematic underestimation of activity concentration in structures that may hold critical diagnostic, treatment, or dosimetric information that impacts patient management. Recovery coefficient (RC)-based partial-volume correction (PVC) is one of the simpler approaches used to correct for partial-volume losses impacting image-based activity estimates in quantitative nuclear medicine. Despite its routine application, RC PVC lacks standardization, underscoring the need for a validated and vetted tool to facilitate consistent use across the community. As part of the MIRDsoft community dosimetry tools project, we have developed MIRDpvc-a worksheet that facilitates a resolution-based RC PVC approach that enables shape-specific corrections, alongside conventional RC curve corrections. In this work, we describe the MIRDpvc software and validate the new PVC methodology using various simulated studies. The recovery coefficient equivalent resolution-geometric mean (RECOVER-GM) model implemented in MIRDpvc represents a straightforward and effective improvement in the quantitative accuracy of mean activity concentrations within volumes of interest in PET and SPECT images, accounting for both spill-out and spill-in PVEs and incorporating shape-specific corrections. The simplicity and accessibility of the software make it practical for clinical implementation, providing a significant improvement over methods that rely on spherical assumptions. The RECOVER-GM method incorporates lesion geometry while maintaining computational efficiency, highlighting its practical advantages for PVC in PET and SPECT imaging.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Varying Levels of Inflammatory Activity in Brain and Body of Patients with Persistent Fatigue and Difficulty Concentrating After COVID-19: A TSPO PET Study.","authors":"Denise Visser, Sandeep S V Golla, Xavier Palard-Novello, Sander C J Verfaillie, Anouk Verveen, Dook W Koch, Roos M Rikken, Elsmarieke van de Giessen, Pythia T Nieuwkerk, Marijke E den Hollander, Janneke Horn, Caroline M van Heugten, Menno D de Jong, Cees C van den Wijngaard, Tessa van der Maaden, Yvonne M G van Os, Maria Prins, Johanna M A Visser-Meily, Patrick Schober, Robert C Schuit, Michael Kassiou, Albert D Windhorst, Sara Biere-Rafi, Brent Appelman, Michele van Vugt, Frederik Barkhof, Bart N M van Berckel, Ronald Boellaard, Hans Knoop, Nelleke Tolboom","doi":"10.2967/jnumed.124.269297","DOIUrl":"https://doi.org/10.2967/jnumed.124.269297","url":null,"abstract":"<p><p>A significant number of patients report persistent fatigue and difficulty concentrating after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a condition known as post-coronavirus disease 2019 (post-COVID) syndrome. The underlying mechanisms for these complaints remain poorly understood. Dysregulated immune and neurologic systems may play a role in the pathophysiology of post-COVID syndrome. A target providing direct information on immune activation is the 18-kDa translocator protein (TSPO), which is upregulated in activated microglia. The PET tracer <i>N,N-</i>diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a]pyrimidin-3-yl)acetamide ([¹⁸F]DPA-714) binds with high affinity to TSPO and serves as a biomarker for neuroinflammation. We aimed to assess whole-body inflammatory activity with TSPO PET in individuals with and without persistent severe fatigue and difficulty concentrating 2 y after infection with SARS-CoV-2 as well as its association with complaint severity. <b>Methods:</b> In this cross-sectional cohort study, we evaluated 47 post-COVID individuals, 33 of whom had severe fatigue and difficulty concentrating (age, 50 ± 8 y; 27 ± 9 mo after initial infection) and 14 who did not have these complaints (age, 47 ± 9 y; 25 ± 10 mo after initial infection). All individuals were high-affinity binders according to their TSPO genotype and completed whole-body 60-min dynamic [¹⁸F]DPA-714 PET with arterial sampling, MRI, genotyping, and questionnaires. Tracer binding was quantified using binding potential for cerebral regions and inhibitory constant or total distribution volume for extracerebral regions. Parameters were compared between 33 individuals with persistent complaints (severe fatigue and difficulty concentrating) and 14 without, and associations between parameters were assessed. <b>Results:</b> We found globally increased cerebral [¹⁸F]DPA-714 binding in some individuals reporting persistent complaints when compared with individuals without these complaints. No group-level differences were found in extracerebral binding. Large variability in cerebral and extracerebral binding was observed among individuals. Cerebral and extracerebral binding levels were not correlated with each other or with complaint severity. <b>Conclusion:</b> Increased specific [¹⁸F]DPA-714 binding was found in some individuals with post-COVID syndrome, indicating the presence of an inflammatory subtype and further supporting the role of neuroinflammation in subtypes of post-COVID syndrome.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FPP-RGD₂ PET Imaging for Interrogating Target Engagement and Antifibrotic Activity of an Integrin Antagonist in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.","authors":"Iris Y Zhou, Caiyuan Zhang, Mozhdeh Sojoodi, Nicholas J Rotile, Yu Lan, Stephen C Barrett, Changning Wang, Caralee J Schaefer, Karl Kossen, Scott D Seiwert, Kenneth K Tanabe, Peter Caravan","doi":"10.2967/jnumed.125.270047","DOIUrl":"https://doi.org/10.2967/jnumed.125.270047","url":null,"abstract":"<p><p>Patient outcomes in metabolic dysfunction-associated steatohepatitis (MASH) are associated with the presence and stage of liver fibrosis. Activated hepatic stellate cells are a key mediator of MASH fibrogenesis and show increased expression of integrin α_vβ₃, making it a promising target for imaging and treatment of liver fibrosis. The ability to noninvasively measure target engagement of integrin inhibitors is key to understanding their chances of success in clinical development. <b>Methods:</b> Target engagement was assessed using PET imaging of an arginine-glycine-aspartic acid (RGD)-based integrin-binding tracer ¹⁸F-FPP-RGD₂ Mice were fed a choline-deficient, ʟ-amino acid-defined, high-fat diet (CDAHFD) or control diet for 2, 6, 10, or 14 wk to induce fibrosis (<i>n</i> = 6/time point). PET was conducted on subsequent days without and with an oral dose of integrin α_vβ₃ antagonist IDL-2965 (10 mg/kg). The antifibrotic activity was evaluated in mice fed CDAHFD for 12 wk and treated with daily oral IDL-2965 (10 mg/kg) or vehicle in weeks 5-12. Integrin β₃ expression was evaluated in liver biopsies from patients with varying degrees of fibrosis. <b>Results:</b> Significantly higher liver uptake of the integrin-binding PET tracer was found in MASH mice than in age-matched controls and increased with the duration of CDAHFD up to 10 wk. At each stage of fibrotic progression, a single oral dose of IDL-2965 significantly reduced hepatic ¹⁸F-FPP-RGD₂ uptake, consistent with strong IDL-2965 target engagement. In a separate study, therapeutic administration of IDL-2965 significantly reduced multiple measures of CDAHFD-induced liver fibrosis, including histologic fibrosis scores, Sirius Red-stained area, hydroxyproline content, Col1α1 messenger RNA expression, and plasma cytokeratin-18. In human liver biopsies, integrin β₃ expression increased with increasing fibrosis score. <b>Conclusion:</b> Increased expression of integrin α_vβ₃ and strong target engagement by IDL-2965 in the CDAHFD-induced MASH model can be detected in vivo using the integrin-binding PET tracer ¹⁸F-FPP-RGD₂ Consistent with strong target engagement, therapeutic administration of IDL-2965 significantly reduced multiple measures of CDAHFD-induced hepatic fibrosis.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncommon Anomalous Biodistribution of ¹⁸F-DCFPyL Prostate-Specific Membrane Antigen: A Case Series.","authors":"Zachary J Drew, Dalveer Singh, Robert Ware, Bi Ying Xie, Peter Jackson, Theodore Lau, Gavin Mackie","doi":"10.2967/jnumed.125.269614","DOIUrl":"10.2967/jnumed.125.269614","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1495-1496"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Isotope to Impact: ²¹¹At.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":"66 9","pages":"6A"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.","authors":"Jahlisa S Hooiveld-Noeken, Laura Kist de Ruijter, Pim P van de Donk, Lotte M Smit, Marjolijn N Lub-de Hooge, Joyce van Sluis, Adrienne H Brouwers, Hartmut Koeppen, Wim Timens, Hendrikus H Boersma, Sjoerd G Elias, Jourik A Gietema, Daan G Knapen, Geke A P Hospers, Simon P Williams, Sandra S Bohorquez, Alexander Ungewickell, Derk-Jan de Groot, Mathilde Jalving, Elisabeth G E de Vries","doi":"10.2967/jnumed.124.269313","DOIUrl":"10.2967/jnumed.124.269313","url":null,"abstract":"<p><p>Whole-body CD8⁺ T-cell PET imaging can detect spatial and temporal localization of CD8⁺ T cells. To obtain insight into early CD8⁺ T-cell response to immunotherapy in patients with melanoma, a highly immunogenic tumor, we performed serial PET imaging with the 1-armed CD8 antibody tracer ⁸⁹ZED88082A. <b>Methods:</b> Immunotherapy-naïve adult patients with stage IV melanoma underwent PET scanning 2 d after receiving 10 mg of ⁸⁹ZED88082A intravenously at baseline and 6-8 wk after initiation of standard-of-care immunotherapy. Tracer uptake in lesions, normal lymph nodes, and Waldeyer ring was assessed using SUV_max; other healthy tissue uptake was assessed using SUV_mean Uptake in tumors and healthy lymph nodes was expressed as the geometric mean SUV_max per patient and in healthy tissue as SUV_mean for all patients. Tumor response was evaluated in accordance with iRECIST version 1.1. Tumor tissue was immunohistochemically stained for CD8. <b>Results:</b> Serial imaging was performed for 10 of 11 enrolled patients. The geometric mean tumor SUV_max was 7.2 (95% CI, 5.6-9.4) before treatment and 7.3 (95% CI, 5.7-9.5; <i>P</i> = 0.89) during treatment, with spatial and temporal heterogeneity in tumor uptake. The spleen demonstrated the highest uptake among healthy tissues, and this value remained similar during treatment. After immunotherapy, 2 patients experienced a complete response, 7 a partial response, and 2 progressive disease. Changes in tumor uptake during treatment did occur but did not correlate with tumor response. Nine evaluable pretreatment tumor tissues showed a CD8-inflamed immune phenotype. <b>Conclusion:</b> Lesions demonstrated spatial and temporal heterogeneity in ⁸⁹ZED88082A uptake within and among patients with melanoma.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1345-1351"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical Therapy: Balancing Absorbed Dose and Antitumor Immunity.","authors":"Jiangtao Yue, Yue Zhang, Yue Miu, Yaqi Zhao, Yue Li, Yicheng Ni, Guanghai Fei","doi":"10.2967/jnumed.125.269868","DOIUrl":"10.2967/jnumed.125.269868","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1499"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetry-Guided [¹³¹I]MIBG Therapy in a Hemodialysis-Dependent Paraganglioma Patient.","authors":"Celeste I Winters, Burcak Yilmaz, Anna M Mench, Catherine A L Meyer, Evan Dodson, Raghav Wusirika, Nadine Mallak, Erik S Mittra","doi":"10.2967/jnumed.125.269513","DOIUrl":"10.2967/jnumed.125.269513","url":null,"abstract":"<p><p>High specific-activity ¹³¹I-metaiodobenzylguanidine ([¹³¹I]MIBG) therapy is approved for patients with pheochromocytoma or paraganglioma. As [¹³¹I]MIBG is not effectively cleared through dialysis, the 2008 European Association of Nuclear Medicine guidelines list renal insufficiency requiring dialysis as a contraindication for [¹³¹I]MIBG treatment. <b>Methods:</b> We describe the clinical and dosimetry findings of a hemodialysis-dependent patient with metastatic paraganglioma who was treated with [¹³¹I]MIBG. <b>Results:</b> The patient tolerated the treatment with acceptable radiation doses to normal organs and effective treatment doses. Radiation safety precautions were followed, and radiation exposures stayed below safe limits for staff. <b>Conclusion:</b> Dosimetry-guided treatment with [¹³¹I]MIBG in patients requiring hemodialysis is feasible. With appropriate dose reduction, the treatment can be effective with limited side effects.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1392-1395"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SUVs Versus Dynamic Pharmacokinetic [¹⁸F]Fluoro-Polyethylene Glycol-Folate Uptake Parameters in Joints of Rheumatoid Arthritis Patients at Baseline and at 4 Weeks of Antitumor Necrosis Factor Therapy.","authors":"Wouter Henk-Jan van Binsbergen, Gerben Johannes Cornelis Zwezerijnen, Albert D Windhorst, Patrick Schober, Alexandre E Voskuyl, Conny J van der Laken, Maqsood Yaqub","doi":"10.2967/jnumed.124.268717","DOIUrl":"10.2967/jnumed.124.268717","url":null,"abstract":"<p><p>Quantitative assessment of rheumatoid arthritis (RA) activity using [¹⁸F]fluoro-polyethylene glycol (PEG)-folate PET/CT scans may prove a useful noninvasive therapeutic response assessment tool to evaluate antitumor necrosis factor therapy in RA patients. This study aims to assess [¹⁸F]fluoro-PEG-folate kinetics through a metabolite-corrected plasma input model and to investigate comparisons with simplified quantitative PET outcome measures. <b>Methods:</b> Dynamic [¹⁸F]fluoro-PEG-folate PET/CT scans were obtained for 6 patients for a total of 11 scans, 6 before and 5 after treatment. These scans were analyzed using conventional pharmacokinetic models. In addition, SUVs were calculated at intervals of 10-40, 20-50, 30-60, and 40-60 min after injection for comparison and imaging window optimization. <b>Results:</b> [¹⁸F]fluoro-PEG-folate kinetics in joints of RA patients were best described using the reversible pharmacokinetic 2-tissue compartment model with a volume of distribution (<i>V_T</i> ) mean of 1.0 (±0.5). <i>V_T</i> values correlated between arterial and venous samples at both baseline (<i>P</i> < 0.001, <i>r</i> ² = 0.96) and 4 wk after antitumor necrosis factor treatment (<i>P</i> < 0.001, <i>r</i> ² = 0.75), both at intervals of 30-60 and 40-60 min. Changes in <i>V_T</i> behavior during treatment could not be accurately assessed because of limited available data, but observed changes in the linear association slope may indicate changed kinetic behavior. <b>Conclusion:</b> The most optimal kinetic model for [¹⁸F]fluoro-PEG-folate uptake in joints of RA patients was the reversible 2-tissue compartment model. The associations between <i>V_T</i> and a simplified SUV interval of 30-60 min allow us to quantify tracer uptake without the need for a full cross-sectional pharmacokinetic evaluation at the time of imaging. Further research will be required to accurately assess the change in tracer behavior between time points and the use of simplified assessment of changes of tracer uptake in joints over time.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1458-1463"},"PeriodicalIF":9.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}